Sacroiliitis as an initial manifestation of acute myelogenons leukemia

被引:12
作者
Hoshino, Takumi
Matsushima, Takafumi
Saitoh, Yasuyuki
Yamane, Arito
Takizawa, Makiko
Irisawa, Hiroyuki
Saitoh, Takayuki
Handa, Hiroshi
Tsukamoto, Norifumi
Karasawa, Masamitsu
Murakami, Hirokazu
Nojima, Yoshihisa
机构
[1] Gunma Univ, Grad Sch Med, Dept Med & Clin Sci, Maebashi, Gumma 3718511, Japan
[2] Gunma Univ, Fac Med, Sch Hlth Sci, Maebashi, Gumma 3718511, Japan
[3] Gunma Univ Hosp, Div Blood Transfus Serv, Gunma, Japan
关键词
sacroiliitis; AML; AS;
D O I
10.1532/IJH97.06106
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sacroiliitis is the most pathognomonic and earliest manifestation of ankylosing spondylitis. We herein report a 28-year-old female patient who presented with sacroiliitis as an initial manifestation of acute myelogenous leukemia (AML). She had a 3-month history of anemia and walking difficulty. Bone marrow findings revealed an increase of blasts with trilineage dysplasia. Although she was initially diagnosed with myelodysplastic syndrome (MDS), blasts rapidly increased and AML developed 1 month after the diagnosis of MDS with sacroiliitis. Induction chemotherapy failed to induce a complete remission of AML, but it did effectively treat the sacroiliitis. However, the sacroiliitis relapsed when the leukemia cells progressed thereafter. Oral corticosteroids helped ameliorate the sacroiliitis. She underwent bone marrow transplantation (BMT) from an HLA-identical sister during a nonremission period; however, the leukemic cells began to rapidly increase from day 30 after BMT. The close relationship between the occurrence of sacroiliitis and AML suggested that autoimmune sacroiliitis was a paraneoplastic phenomenon of AML in this patient. Although autoimmune disorders develop in a substantial number of MDS patients, they are rarely observed in de novo AML. No previous report has described sacroiliitis as the initial manifestation of de novo AML.
引用
收藏
页码:421 / 424
页数:4
相关论文
共 13 条
[1]   Risk of haematological malignancies in HLA-B27 carriers [J].
Au, WY ;
Hawkins, BR ;
Cheng, N ;
Lie, AKW ;
Liang, R ;
Kwong, YL .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (02) :320-322
[2]   Acute myelogenous leukaemia following etanercept therapy [J].
Bakland, G ;
Nossent, H .
RHEUMATOLOGY, 2003, 42 (07) :900-901
[3]  
BILLSTROM R, 1995, EUR J HAEMATOL, V55, P42
[4]  
CASTRO M, 1991, J RHEUMATOL, V18, P721
[5]   IMMUNE ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES [J].
ECONOMOPOULOS, T ;
ECONOMIDOU, J ;
GIANNOPOULOS, G ;
TERZOGLOU, C ;
PAPAGEORGIOU, E ;
DERVENOULAS, J ;
ARSENI, P ;
HADJIOANNOU, J ;
RAPTIS, S .
JOURNAL OF CLINICAL PATHOLOGY, 1985, 38 (08) :908-911
[6]   PARANEOPLASTIC AUTOIMMUNE PHENOMENA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES - RESPONSE TO IMMUNOSUPPRESSIVE THERAPY [J].
ENRIGHT, H ;
JACOB, HS ;
VERCELLOTTI, G ;
HOWE, R ;
BELZER, M ;
MILLER, W .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 91 (02) :403-408
[7]  
Hamblin TJ, 1996, SEMIN HEMATOL, V33, P150
[8]   First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients [J].
Koch, B ;
Kranzhöfer, N ;
Pfreundschuh, M ;
Pees, HW ;
Trümper, L .
BONE MARROW TRANSPLANTATION, 2000, 26 (06) :673-675
[9]   IMMUNOLOGICAL ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES .1. SERUM IMMUNOGLOBULINS AND AUTOANTIBODIES [J].
MUFTI, GJ ;
FIGES, A ;
HAMBLIN, TJ ;
OSCIER, DG ;
COPPLESTONE, JA .
BRITISH JOURNAL OF HAEMATOLOGY, 1986, 63 (01) :143-147
[10]  
Okamoto T, 1997, INT J HEMATOL, V66, P345